COVID-19 Does Not Seriously Affect Children With PH, Texas Study Finds
COVID-19 tends not to cause serious illness or death in children with pulmonary hypertension (PH), but its long-term consequences remain unknown, according to a study in a center in Texas.
The study, “Outcomes of COVID-19 infection in pediatric pulmonary hypertension: a single-center experience, ”Was published in the journal Pediatric pulmonology.
At the start of the COVID-19 pandemic, it was clear that people with certain underlying conditions were particularly vulnerable to the disease. While it was initially feared that people with PH are very susceptible to COVID-19, emerging research has indicated that this is likely not the case for adults.
Beaucoup de choses sont encore inconnues sur COVID-19. Par exemple, on sait peu de choses sur la façon dont le virus affecte les enfants. De même, il existe peu de données sur les résultats pour les enfants atteints d’HTP qui contractent la COVID-19.
Maintenant, les chercheurs ont signalé 23 cas de COVID-19 chez des enfants recevant des soins au centre de santé publique du Texas Children’s Hospital. Parmi ces enfants, l’âge médian était de 58 mois (un peu moins de cinq ans). Un peu moins de la moitié (48 %) étaient hispaniques, tandis que 22 % étaient blancs, 17 % étaient afro-américains et 13 % étaient asiatiques. Onze patients étaient sous assistance respiratoire, telle qu’une canule nasale continue.
La fréquence des infections était plus élevée chez les Hispaniques que ce à quoi on pourrait s’attendre sur la base des caractéristiques démographiques de l’hôpital d’environ un tiers des patients étant hispaniques, ont noté les chercheurs.
« Cette découverte est très probablement due à notre démographie locale ; cependant, le SRAS-CoV-2 [the virus that causes COVID-19] has been reported more frequently in racial minorities, with Hispanics being the race / ethnic group most affected by this disease nationwide, ”they wrote.
Of the 23 patients, eight (35%) were hospitalized due to COVID-19. Of these, six had congenital heart disease and the same number used breathing assistance. A battery of statistical tests did not identify any factor significantly associated with an increased risk of hospitalization.
The median length of hospital stay was six days. A child, who had failing Fontan’s physiology (a form of heart failure), died.
Five children who developed COVID-19, and two who were hospitalized, have trisomy 21 (Down syndrome). The results in these children were generally comparable to the results in children without Down’s syndrome, unlike previous data for adults.
“This study supports that the COVID-19 disease does not generally or seriously affect pediatric patients with PH, and mortality from this disease is rare,” the researchers concluded.
All but two of the 23 patients underwent a follow-up assessment a median of 101 days after their COVID-19 infection. In most cases, heart health assessments showed no substantial change, although some children experienced marked worsening of physical and lung function assessments after recovering from COVID-19.
PH-specific therapy (including treatments known as phosphodiesterase 5 inhibitors and endothelin receptor antagonists) was intensified in four children, two of whom were on dual therapy and two others were on triple therapy. . One patient required a temporary increase in nasal cannula breathing support, with higher oxygen flow for five months after COVID-19.
Scientists noted the need for more research, as “the long-term results of COVID-19 disease remain unknown.”